Why aren’t pharmaceutical companies interested in exploring the possibility of LDN as an MS therapy?
Naltrexone was developed so long ago, it is now a generic drug, manufactured by many different companies. Since no single company owns exclusive manufacturing rights, Naltrexone can be manufactured and sold very inexpensively by any pharmaceutical company. This means that LDN can’t make anyone any money. Pharmaceutical companies are not eager to fund clinical trials for a drug that will make them no profit. Also, if LDN were FDA-approved and became a preferred treatment for MS, the pharmaceutical companies who make the expensive ABCR drugs could lose millions of dollars.
